/
RLMD
$5.35+$0.21 (+4.09%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$561.7M
105M shares
52-week range
$0.55 – $8.00
64% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-20.36
Relmada Therapeutics, Inc. Common Stock
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
www.relmada.com- Employees
- 17
- IPO / List date
- Mar 3, 2014
- HQ
- CORAL GABLES, FL
Held by traders on TradeandTell
No one on the platform currently holds RLMD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 167,200 | $1.2M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-09-30 | 1-for-4reverse |
| 2015-08-12 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded RLMD yet.
